Bristol Myers Squibb has become the latest Big Pharma to tie up a biotech pact as we reach the year’s end, tapping Harbour ...

Harbour is eligible for payments of $90m, with potential development and commercial milestones of up to $1.035bn.

The Phase IIb study will enroll approximately 87 participants and evaluate two therapeutic doses of psilocybin against a low-dose comparator, combined with structured psychotherapy. With multiple ...

Sino-US biotech Harbour BioMed, which is focused on the discovery and development of novel antibody therapeutics in ...

SHANGHAI, CAMBRIDGE, Mass. and ROTTERDAM, Netherlands, /PRNewswire/ -- Harbour BioMed (HKEX: 02142), a global ...

Harbour BioMed announced it has entered a multi-year, global strategic collaboration and license agreement with Bristol Myers ...

Orchestra BioMed has announced that the FDA has granted Breakthrough Device Designation for its atrioventricular interval modulation (AVIM) therapy, aimed at treating over 7.7 million U.S. patients ...

Harbour BioMed, a global biopharmaceutical company, has announced a multi-year, global strategic collaboration and license ...

However, When quite a few insiders buy shares, as it happened in Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) case, it's fantastic news for shareholders. Although we don't think shareholders should ...

Orchestra BioMed reported that it has secured over $111 million in financing through a series of transactions and offerings—supported by deals with Medtronic and Ligand Pharmaceuticals—as it looks to ...